Acetylator phenotype and lupus erythematosus.
There are several known therapeutic implications of acetylator phenotype; among them, the association of a higher incidence of procainamide- and hydralazine-induced lupus in slow acetylators. Presumably, this is because acetylation of the aromatic amine or hydrazine functional group leads to a non-toxic product. Several other drugs which have been implicated in drug-induced lupus also contain an aromatic amine or hydrazine group. The clinical and laboratory characteristics of drug-induced and idiopathic lupus are similar but the degree to which the pathophysiological mechanisms are related, if at all, is unknown. There is also evidence reported for an association between the slow acetylator phenotype and idiopathic lupus. If true, this relationship should provoke some new experimental approaches to investigation into the mechanism of idiopathic lupus.
D000107:Acetylation; D000123:Acetyltransferases / Q000378:metabolism; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D011342:Procainamide / Q000009:adverse effects
D006830:Hydralazine; D000123:Acetyltransferases; D011342:Procainamide